New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
08:01 EDTAMGNXencor initiates Phase 1b/2a trial of XmAb5871
Xencor announced that the first patient has been dosed in a Phase 1b/2a clinical trial of XmAb5871 in patients with moderate to severe rheumatoid arthritis.  XmAb5871 is the first in a new class of therapeutic antibodies targeting the CD32b pathway in B cells, which shows potential to suppress autoimmune disorders without the side effects caused by B cell depletion. The trial initiation triggered a milestone payment of an undisclosed amount to Xencor from Amgen. XmAb5871 is a humanized and Fc engineered monoclonal antibody that uses a uniquely selective dual-targeting mechanism for B cell inhibition by co-engaging CD19 and CD32b. Amgen and Xencor entered into an option and co-development agreement for XmAb5871 in January 2011. Amgen has the option to an exclusive worldwide license following the completion of a pre-defined Phase 2 study. Xencor will lead all clinical development until that time and is eligible for early development milestone payments.
News For AMGN From The Last 14 Days
Check below for free stories on AMGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
13:56 EDTAMGNAmgen sell-off creates buying opportunity, says Argus
After Amgen reported weaker than expected Q1 results, Argus believes that the company's key growth drivers performed well last quarter. The firm thinks the company's growth outlook looks solid, and it keeps a Buy rating on the shares.
09:34 EDTAMGNActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD NFLX TSLA VZ MU WFM AMGN
09:16 EDTAMGNOn The Fly: Pre-market Movers
Subscribe for More Information
07:53 EDTAMGNAmgen weakness a buying opportunity, says Cowen
Cowen would use any weakness in Amgen as buying opportunity and said the recent shortfall was due to seasonal factors and that 2014 remains on track. The firm cited company guidance, its superior profile relative to peers, potential for increased dividends, and a maturing pipeline. Shares are Outperform rated with a $131 price target.
06:54 EDTAMGNCambridge Healthtech Institute to hold a conference
Subscribe for More Information
06:53 EDTAMGNFood & Drug Law Institute to hold a conference
Subscribe for More Information
April 22, 2014
16:32 EDTAMGNAmgen says total product sales declined 9% sequentially in Q1
Subscribe for More Information
16:25 EDTAMGNAmgen trades lower after results, first look
Subscribe for More Information
16:06 EDTAMGNAmgen sees FY14 EPS $7.90-$8.20, consensus $8.16
Subscribe for More Information
16:05 EDTAMGNAmgen reports Q1 EPS $1.87, consensus $1.94
Subscribe for More Information
15:32 EDTAMGNNotable companies reporting after market close
Subscribe for More Information
14:35 EDTAMGNEarnings Preview: Amgen's timeline for Evolocumab will be in focus
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use